Contact Us
United States - English
China - 简体中文China - 繁體中文Germany – DeutschJapan - 日本語Switzerland - FrançaisUnited States - English

WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.
Filter By
All Years

2016/02/02

WuXi AppTec Congratulates MSD on Receiving FDA Approval of ZEPATIER™

SHANGHAI, February 2, 2016 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, congratulates MSD, known as Merck & Co., Inc. in the United States and Canada, for receiving approval from the FDA for ZEPATIER™ (elbasvir / grazoprevir) for the treatment of adult patients with chronic hepatitis C virus, genotypes 1 or 4.

Read more

2016/01/08

WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group

SHANGHAI, January 8, 2016 -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, today congratulated Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

Read more

2015/12/10

WuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction

WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the completion of its merger (the "Merger") with WuXi Merger Limited("Merger Sub"), a wholly-owned subsidiary of New WuXi Life Science Limited ("Parent"), pursuant to the previously announced Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2015 and amended on October 20, 2015 and November 20, 2015, among the Company, Parent and Merger Sub. As a result of the Merger, Parent has acquired the Company (which is now a direct wholly owned subsidiary of Parent) in a cash transaction valued at approximately US$3.3 billion.

Read more

2015/12/08

WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China

SHANGHAI and RALEIGH N.C., December 8, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and PRA Health Sciences, Inc. (NASDAQ: PRAH), a leading global clinical contract research organization, today announced a restructuring of their relationship for the delivery of clinical trial management services in China, Macau and Hong Kong. The two companies formed a joint venture for this purpose in March 2013.

Read more

2015/12/07

Dr. Ge Li Receives Executive of the Year Award from SCRIP

SHANGHAI, Dec. 7, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that Dr. Ge Li, WuXi's Chairman and CEO, was named Executive of the Year at the 11th annual SCRIP Awards on December 2 in London. Established by SCRIP Intelligence, a leading industry news and strategic analysis firm covering the global pharmaceutical and biotech industry, the annual SCRIP Awards recognize the industry's highest achievements by both companies and individuals across the value chain.

Read more